YSP Southeast Asia Holding Bhd banner
Y

YSP Southeast Asia Holding Bhd
KLSE:YSPSAH

Watchlist Manager
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Watchlist
Price: 2.1 MYR Market Closed
Market Cap: 297.9m MYR

P/S

0.8
Current
14%
Cheaper
vs 3-y average of 0.9

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
0.8
=
Market Cap
MYR293.6m
/
Revenue
365.1m

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
0.8
=
Market Cap
MYR293.6m
/
Revenue
365.1m

Valuation Scenarios

YSP Southeast Asia Holding Bhd is trading below its 3-year average

If P/S returns to its 3-Year Average (0.9), the stock would be worth MYR2.43 (16% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+138%
Average Upside
70%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 0.8 MYR2.1
0%
3-Year Average 0.9 MYR2.43
+16%
5-Year Average 0.9 MYR2.44
+16%
Industry Average 1.9 MYR4.99
+138%
Country Average 1.7 MYR4.42
+110%

Forward P/S
Today’s price vs future revenue

Not enough data available to calculate forward P/S

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
MY
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
297.9m MYR 0.8 11.9
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 12.4 39.1
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 5.7 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.2 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 4.8 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 4.8 19.5
US
Merck & Co Inc
NYSE:MRK
272.3B USD 4.2 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 3.7 11.1
US
Pfizer Inc
NYSE:PFE
150.6B USD 2.4 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 2.4 16.6
P/E Multiple
Earnings Growth PEG
MY
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Average P/E: 20.6
11.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.1
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

Lower than 74% of companies in Malaysia
Percentile
26th
Based on 482 companies
26th percentile
0.8
Low
0 — 0.9
Typical Range
0.9 — 3
High
3 —
Distribution Statistics
Malaysia
Min 0
30th Percentile 0.9
Median 1.7
70th Percentile 3
Max 5 877.6

YSP Southeast Asia Holding Bhd
Glance View

Market Cap
297.9m MYR
Industry
Pharmaceuticals

Y.S.P.Southeast Asia Holding Bhd. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2004-01-12. Southeast Asia Holding Bhd. is a Malaysia-based investment holding company that is primarily engaged in the provision of management services. The Company’s segments include Manufacturing, Trading and Investment holding. The Manufacturing segment is engaged in manufacturing of pharmaceutical products. The Trading segment is involved in import, export and trading of various kinds of pharmaceutical, traditional herbal and veterinary products. The Investment holding segment is engaged in investment holding. Its subsidiaries include Y.S.P. (Cambodia) Pte. Ltd., which is engaged in providing management services, such as product registration trademark registration and national marketing and trading in all kinds of pharmaceutical products, and Alpha Active Industries Sdn. Bhd., which is engaged in the manufacture of biotechnology products and health products.

YSPSAH Intrinsic Value
3.01 MYR
Undervaluation 30%
Intrinsic Value
Price MYR2.1
Y
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett